<DOC>
	<DOC>NCT01550848</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and toxicity of Abraxane combined with Gemcitabine in the patients with metastatic breast cancer.</brief_summary>
	<brief_title>A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>This study is to investigate the efficacy and toxicity of Abraxane combined with Gemcitabine in the patients with metastatic breast cancer.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Female between 18 and 70 years old; Patients with histologic proved metastatic breast cancer, unsuitable to be treated with surgery; ECOG (Eastern Cooperative Oncology Group) 0~1; Normal functions with heart, liver,renal and bone marrow:WBC≥3.5×109/L；Hb≥90 g/L；plt≥100×109/L; Got ICF (Informed Consent Form) before enrollment; Life expectancy more than 12 weeks Pregnant or breastfeeding women or positive serum pregnancy test; Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling; Participation in any investigational drug study within 4 weeks preceding treatment start; Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer; Serious uncontrolled intercurrent infections; Poor compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>